相关实验视频

Updated: Jan 12, 2026

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

凯托提芬重新酸化分泌溶解体,并使巨细胞的衰老表型正常化

Lorenzo Barrella¹, María Pilar Ramírez-Ponce¹, Victoria Vázquez-Román²

¹Dpto. de Fisiología Médica y Biofísica. Facultad de Medicina. Universidad de Sevilla, Spain.

Biochemical and biophysical research communications

|November 1, 2025

概括

溶解体pH值随着年龄的增长而降低,从而影响瘤细胞 (MCs) 的功能. 凯托蒂芬治疗可以逆转这种与年龄相关的脱酸,恢复 lysosomal 酸度并减轻 MC 驱动的炎症.

科学领域:

细胞生物学细胞生物学
免疫学免疫学免疫学
衰老研究研究衰老研究

背景情况:

乳腺细胞 (MCs) 是关键的免疫细胞,具有分泌溶酶体颗粒,需要酸性光线才能发挥作用.
溶解体pH调节对细胞过程至关重要,其与年龄相关的变化尚未完全理解.

研究的目的:

为了研究巨细胞溶酶体pH的年龄相关变化.
为了确定基托蒂芬是否可以逆转衰老巨细胞中的溶酶体脱酸.

主要方法:

腹性巨细胞的奎纳克林成像,以评估溶酶体pH.
药理学试验评估基托提芬的作用机制,包括V-ATPase活性和内细胞分裂.
托卢伊丁蓝色染色用于分析大脑组织中的乳腺细胞形态.

主要成果:

溶解体pH从15到17个月的乳腺细胞中逐渐降低.
慢性基托提芬治疗恢复了溶酶体酸度,增加了颗粒体大小,并减少了巨细胞扩张.
凯托蒂芬的重新酸化效应取决于V-ATPase活性和动氨酸依赖性内细胞分裂,增强内细胞活性.
开托提芬治疗逆转了大脑中与年龄相关的乳腺细胞缩.

结论:

溶酶体脱酸是巨细胞衰老的一个重要标志.
凯托蒂芬有效地通过V-ATPase和内细胞分裂重新酸化分泌溶解体.
向溶酶体pH值代表了一种有前途的策略,以对抗由巨细胞驱动的与年龄相关的炎症.

关键词:

年龄化衰老衰老细胞内存症是指细胞内存症.凯托提芬 (Ketotifen) 是一种饮食方式.Lysosomal 酸性化发生的原因巨细胞是巨细胞.这是一个V-ATPase.

更多相关视频

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.